Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?

Sarah R Verhoeff; Michel M van den Heuvel; Carla M L van Herpen; Berber Piet; Erik H J G Aarntzen; Sandra Heskamp

doi:10.1016/j.cpet.2019.08.008

Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?

Sarah R Verhoeff
, Michel M van den Heuvel
, Carla M L van Herpen
, Berber Piet
, Erik H J G Aarntzen
, Sandra Heskamp

Research output: Contribution to journal › Review article › peer-review

Abstract

Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.

Original language	English
Pages (from-to)	35-43
Number of pages	9
Journal	PET Clinics
Volume	15
Issue number	1
DOIs	https://doi.org/10.1016/j.cpet.2019.08.008
Publication status	Published - Jan 2020
Externally published	Yes

Keywords

Antineoplastic Agents, Immunological/therapeutic use
B7-H1 Antigen/antagonists & inhibitors
Biomarkers, Tumor/metabolism
Clinical Trials as Topic
Forecasting
Humans
Immunotherapy/methods
Neoplasms/diagnostic imaging
Positron Emission Tomography Computed Tomography/methods
Positron-Emission Tomography/methods
Tomography, Emission-Computed, Single-Photon/methods
Tumor Microenvironment

Access to Document

10.1016/j.cpet.2019.08.008Licence: CC BY-NC-ND

Cite this

@article{34dd2583b9ad43029a81d04df98da973,

title = "Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?",

abstract = "Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.",

keywords = "Antineoplastic Agents, Immunological/therapeutic use, B7-H1 Antigen/antagonists \& inhibitors, Biomarkers, Tumor/metabolism, Clinical Trials as Topic, Forecasting, Humans, Immunotherapy/methods, Neoplasms/diagnostic imaging, Positron Emission Tomography Computed Tomography/methods, Positron-Emission Tomography/methods, Tomography, Emission-Computed, Single-Photon/methods, Tumor Microenvironment",

author = "Verhoeff, \{Sarah R\} and \{van den Heuvel\}, \{Michel M\} and \{van Herpen\}, \{Carla M L\} and Berber Piet and Aarntzen, \{Erik H J G\} and Sandra Heskamp",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2020",

month = jan,

doi = "10.1016/j.cpet.2019.08.008",

language = "English",

volume = "15",

pages = "35--43",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Programmed Cell Death-1/Ligand-1 PET Imaging

T2 - A Novel Tool to Optimize Immunotherapy?

AU - Verhoeff, Sarah R

AU - van den Heuvel, Michel M

AU - van Herpen, Carla M L

AU - Piet, Berber

AU - Aarntzen, Erik H J G

AU - Heskamp, Sandra

PY - 2020/1

Y1 - 2020/1

N2 - Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.

AB - Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.

KW - Antineoplastic Agents, Immunological/therapeutic use

KW - B7-H1 Antigen/antagonists & inhibitors

KW - Biomarkers, Tumor/metabolism

KW - Clinical Trials as Topic

KW - Forecasting

KW - Humans

KW - Immunotherapy/methods

KW - Neoplasms/diagnostic imaging

KW - Positron Emission Tomography Computed Tomography/methods

KW - Positron-Emission Tomography/methods

KW - Tomography, Emission-Computed, Single-Photon/methods

KW - Tumor Microenvironment

U2 - 10.1016/j.cpet.2019.08.008

DO - 10.1016/j.cpet.2019.08.008

M3 - Review article

C2 - 31735300

SN - 1556-8598

VL - 15

SP - 35

EP - 43

JO - PET Clinics

JF - PET Clinics

IS - 1

ER -

Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?

Abstract

Keywords

Access to Document

Fingerprint

Cite this